{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-015722","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.201308+00:00","generated_at":"2026-06-22T19:04:49.069395+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Harmony Biosciences Q3 2022 net revenue $117.2M, up 45% YoY; GAAP EPS $1.44, non-GAAP EPS $0.95","bullets":["Net product revenue $117.2M (+45% vs Q3 2021); average WAKIX patients ~4,600.","GAAP net income $87.9M ($1.44 diluted EPS) vs loss of $9.6M in prior year; includes $74.5M tax benefit.","Non-GAAP adjusted net income $58.1M ($0.95 diluted EPS) vs $23.4M ($0.41) in prior year.","PWS Phase 2 POC study positive signal on EDS; high-dose pitolisant higher responder rate vs placebo.","Cash, cash equivalents & investments $316M as of Sep 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-015722","json":"https://secwatch.observer/filing/0001558370-22-015722.json","markdown":"https://secwatch.observer/filing/0001558370-22-015722.md","text":"https://secwatch.observer/filing/0001558370-22-015722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/0001558370-22-015722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/hrmy-20221101x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:04:49.069395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7b5953e0f4af963360ca7bad1eb36b029ece75e","claim":"Harmony Biosciences Holdings, Inc. reported the quarter ended September 30, 2022 results: revenue $117.2 million, net income $87.9 million, EPS $1.44 per diluted share.","evidence_excerpt":"reference. --- EX-99.1 (EX-99.1) --- ‌ Exhibit 99.1 ​ HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 ​ Average Number of Patients on WAKIX Increased to ~4,600 ​ Prader-Willi Syndrome (PWS) Phase 2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837022015722/0001558370-22-015722-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$117.2 million"},{"label":"Net income","value":"$87.9 million"},{"label":"EPS","value":"$1.44 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}